Personalized Medicines

Global Personalized Medicines Market to Reach US$822.3 Billion by 2030

The global market for Personalized Medicines estimated at US$629.6 Billion in the year 2024, is expected to reach US$822.3 Billion by 2030, growing at a CAGR of 4.6% over the analysis period 2024-2030. Personalized Nutrition & Wellness, one of the segments analyzed in the report, is expected to record a 4.4% CAGR and reach US$484.0 Billion by the end of the analysis period. Growth in the Personalized Medical Care segment is estimated at 4.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$169.0 Billion While China is Forecast to Grow at 4.3% CAGR

The Personalized Medicines market in the U.S. is estimated at US$169.0 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$130.3 Billion by the year 2030 trailing a CAGR of 4.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.1% and 3.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.5% CAGR.

Global Personalized Medicines Market - Key Trends and Drivers Summarized

Personalized medicine (PM) represents a transformative shift in healthcare, moving away from the traditional one-size-fits-all approach to a more tailored strategy based on individual genetic, epigenomic, and clinical profiles. This method enhances the efficacy of treatments, reduces side effects, and curtails overall healthcare costs by using detailed genomic and epigenomic data to personalize medical treatments precisely. Unlike conventional methods, personalized medicine adjusts treatments to the unique genetic composition of each individual, improving outcomes and reducing the risk of adverse reactions. This approach extends beyond treatment to prevention, utilizing genetic markers and other biomarkers to identify disease risk factors early, potentially preventing disease onset.

The technological advancements in molecular medicine, such as CRISPR-Cas9 gene editing and the development of monoclonal antibodies, are revolutionizing personalized medicine by enabling highly specific therapies that target disease mechanisms precisely. This specificity minimizes collateral damage to healthy cells and enhances treatment efficacy. Furthermore, artificial intelligence (AI) and machine learning are playing an increasingly critical role in personalized medicine by analyzing the vast datasets generated from genomic sequencing. These technologies help identify patterns and speed up the discovery of new therapeutic targets, thereby improving the customization and effectiveness of medical treatments. The proactive nature of personalized medicine not only improves the accuracy of diagnoses and treatment plans but also allows for more effective disease prevention strategies, which can be more cost-effective over time.

Despite its immense potential, personalized medicine faces several challenges that must be addressed to realize its full potential. The high costs of genetic testing and the integration of sophisticated personalized medicine technologies into mainstream healthcare practice are significant barriers. Additionally, ethical considerations and the need to protect patient privacy are paramount to maintaining trust in the use of genetic data for medical purposes. The field of personalized medicine is also influenced by an increased understanding of the genetic bases of diseases, growing demand for more effective treatments tailored to individual needs, and significant cost savings opportunities for healthcare systems. Moreover, regulatory support and the advancement of AI and machine learning are enhancing the predictive power of personalized medicine, making it an indispensable tool in clinical decision-making. As personalized medicine continues to evolve, it is set to redefine healthcare practices by providing more precise, predictive, and effective medical treatments tailored to the genetic profiles of individual patients, thereby enhancing the overall quality of care and patient outcomes.

SCOPE OF STUDY:

The report analyzes the Personalized Medicines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product (Personalized Nutrition & Wellness, Personalized Medical Care, Personalized Medicine Diagnostics, Personalized Medicine Therapeutics)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 87 Featured) -

• Abbott Molecular
• Beckman Coulter, Inc.
• bioMérieux SA
• Bristol-Myers Squibb Company
• Dako Denmark A/S
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline Plc
• Hologic, Inc.
• Lab 21 Limited
• Macrogen, Inc.
• NeoGenomics Laboratories, Inc.
• Novartis AG
• QIAGEN NV
• Rosetta Genomics Ltd.
• Thermo Fischer Scientific Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.